Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes

被引:38
作者
Lewis, DFV [1 ]
机构
[1] Univ Surrey, Sch Biomed & Life Sci, Mol Toxicol Grp, Guildford GU2 7XH, Surrey, England
关键词
cytochromes P450; drug metabolism; CYP2; family; enzyme models;
D O I
10.1016/S0003-9861(02)00349-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A detailed analysis of substrate selectivity within the cytochrome P450 2 (CYP2) family is reported. From a consideration of specific interactions between drug substrates for human CYP2 family enzymes and the putative active sites of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1, it is likely that the number and disposition of hydrogen bond donor/acceptors and aromatic rings within the various P450 substrate molecules determines their enzyme selectivity and binding affinity, together with directing their preferred routes of metabolism by the CYP2 enzymes concerned. Although many aliphatic residues are present in most P450 active sites, it would appear that their main contribution centers around hydrophobic interactions and desolvation processes accompanying substrate binding. Molecular modeling studies based on the recent CYP2C5 crystal structure appear to show close agreement with site-directed mutagenesis experiments and with information on substrate metabolism and selectivity within the CYP2 family. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:32 / 44
页数:13
相关论文
共 97 条
[1]   Cytochromes P450 and metabolism of xenobiotics [J].
Anzenbacher, P ;
Anzenbacherová, E .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (5-6) :737-747
[2]  
Bachmann Kenneth A., 1996, Am J Ther, V3, P150, DOI 10.1097/00045391-199602000-00009
[3]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[4]  
BORN SL, 1995, DRUG METAB DISPOS, V23, P702
[5]   Genetic polymorphism of CYP2A6 in the German population [J].
Bourian, M ;
Gullstén, H ;
Legrum, W .
TOXICOLOGY, 2000, 144 (1-3) :129-137
[6]  
BROWN D, 2000, WASHINGTON POST 0612, pA9
[7]  
Chang TKH, 1996, CYTOCHROMES P450 MET, P99
[8]   Different structural requirements at specific proline residue positions in the conserved proline-rich region of cytochrome P450 2C2 [J].
Chen, CD ;
Kemper, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (45) :28607-28611
[9]   The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210
[10]  
CUPPVICKERY JR, 1995, STRUCT BIOL, V2, P144